Salarius Pharmaceuticals, Inc.
SLRX
$0.698
-$0.0348-4.75%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 44.22% | -41.89% | -22.62% | -9.82% | -49.19% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 53.36% | -60.25% | -63.05% | -67.32% | -85.02% |
| Operating Income | -53.36% | 60.25% | 63.05% | 67.32% | 85.02% |
| Income Before Tax | -66.01% | 60.21% | 63.26% | 67.88% | 86.16% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -66.01% | 60.21% | 63.26% | 67.88% | 86.16% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66.01% | 60.21% | 63.26% | 67.88% | 86.16% |
| EBIT | -53.36% | 60.25% | 63.05% | 67.32% | 85.02% |
| EBITDA | -53.42% | 60.21% | 63.06% | 67.33% | 85.03% |
| EPS Basic | 43.32% | 85.43% | 79.28% | 81.69% | 92.09% |
| Normalized Basic EPS | 43.32% | 85.43% | 79.28% | 81.69% | 92.09% |
| EPS Diluted | 43.32% | 85.43% | 79.28% | 81.69% | 92.09% |
| Normalized Diluted EPS | 43.32% | 85.43% | 79.28% | 81.69% | 92.09% |
| Average Basic Shares Outstanding | 192.92% | 173.15% | 77.32% | 75.35% | 74.96% |
| Average Diluted Shares Outstanding | 192.92% | 173.15% | 77.32% | 75.35% | 74.96% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |